Eli Lilly (LLY) and Incyte (INCY) said Saturday that a phase 3 study of baricitinib saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes in adolescent patients with severe alopecia areata at week 36.

The results were comparable to the data achieved by adult patients after 52 weeks, indicating that hair regrowth may be faster in adolescents than in adults, according to the companies.

The companies said the results showed 42.4% of adolescents receiving baricitinib 4 mg and 27.4% of patients receiving baricitinib 2mg achieved 80% or more scalp hair coverage at week 36.

Baricitinib was discovered by Incyte and licensed to Lilly. It's approved in the US as treatment for adult patients with severe alopecia areata